Botanix Pharmaceuticals taps investors for $40m; Euroz, E&P in tow
Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for a $40 million equity raise on Monday morning.
The company had Euroz Hartleys and E&P Capital offering shares at 33¢ each – a 7 per cent discount to the last traded price and 13.8 per cent lower than the 10-day volume-weighted average price.
Botanix told investors the funds would accelerate the commercialisation of Sofdra in the United States – a prescription anticholinergic medicine used on the skin to treat excessive underarm sweating.
More to come.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $323.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.0¢ | $3.657M | 21.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 180978 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 529694 | 12 |
View Market Depth
| Last trade - 16.18pm 28/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |